Cardiology

Semaglutide demonstrates significant symptom improvement and enhanced mobility in individuals with heart failure with preserved ejection fraction, obesity

 In the Phase 3 STEP HFpEF trial, once-weekly semaglutide 2.4 mg was found to have significant benefits for adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The results showed notable reductions in heart failure symptoms, improved physical abilities, enhanced exercise function, and greater weight loss compared to...